Welcome to our dedicated page for Enigmatig news (Ticker: EGG), a resource for investors and traders seeking the latest updates and insights on Enigmatig stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Enigmatig's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Enigmatig's position in the market.
Enigmatig Limited (NYSE American: EGG) reported strong financial results for H1 FY2025, marking a significant turnaround with a net profit of US$1.2 million compared to a net loss in the previous year. The company's corporate services income surged by 112.1% YoY to US$2.9 million, driven by robust growth in license application services (158% increase) and corporate secretarial services (90.2% increase).
The company demonstrated substantial margin improvement, with gross profit increasing by 192.1% to US$2.2 million and gross margin expanding to 74.8% from 54.3%. Following its NYSE American IPO in June 2025, which raised US$15.0 million, Enigmatig has strengthened its global presence with offices in Singapore, Hong Kong, Shanghai, London, and a Bangkok representative desk.
FAQ
What is the current stock price of Enigmatig (EGG)?
What is the market cap of Enigmatig (EGG)?
